A Look At PropThink’s Top Stories This Week
Most Popular - Between Keryx and its Japanese partner JT Torii, four clinical trials for lead candidate Zerenex are set to report data over the coming months. The … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Limited Downside With Potential Bidding War Upside For GNOM
Long Ideas - With the latest developments on the proposals to acquire Complete Genomics (NASDAQ:GNOM), investors have the chance to own shares of the life sciences company with … Continue Reading
Read nowProducers of Obesity Drugs Rally on Aetna Update
Most Popular - Weight-loss drug makers popped Wednesday morning after mega-insurer Aetna (NYSE:AET) issued a bulletin on weight reduction medications and procedures. Qysmia, from Vivus (NASDAQ:VVUS), and Arena’s … Continue Reading
Read nowILMN Makes Compelling Argument To Acquire GNOM At Higher Price
Long Ideas - BGI-Shenzhen has extended the acceptance deadline for its $3.15 per share tender offer for Complete Genomics (NASDAQ:GNOM), but the elephant in the room – or … Continue Reading
Read nowMedtronic Continues Growth; Shares Up 10% YTD
Quick Picks - Medtronic Inc. (NYSE:MDT) posted in-line adjusted earnings and a slight revenue miss in the second quarter of its fiscal year 2013, but expects overall sales growth for … Continue Reading
Read nowArena Pharmaceuticals: Q3 Review and the Road Ahead for Belviq
Long Ideas - The biotechnology sector is no stranger to battleground stocks. Companies such as Dendreon (NASDAQ:DNDN) serve as solid examples of this fact. But perhaps no biotechnology … Continue Reading
Read nowWhat To Expect From KERX’s Upcoming Phase III Results For Zerenex; Low Risk/High Reward Prospects
Long Ideas - In the next several weeks, Keryx Biopharmaceuticals (KERX) will release results from 4 key Phase III trials for its primary drug candidate, Zerenex. The drug … Continue Reading
Read now